Hepatic Dysfunction in Renal Carcinoma

Fletcher, M. S.; Packham, D. A.; Pryor, John P.; Yates-Bell, A. J.

doi:10.1111/j.1464-410x.1981.tb03255.x

Cited by 11 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data on the outcome, prognosis, and significance of Stauffer's syndrome is limited. Previous anecdotal reports suggested that RCC patients with hepatic dysfunction had significantly worse prognosis than those without hepatic dysfunction [2,15] . It has also been suggested that the occurrence of Stauffer's syndrome may be an early indicator of recurrence after surgical resection or tumor metastases [15,16] .…”

Section: Al-taee Am Et Al Non-metastatic Hepatic Dysfunctionmentioning

confidence: 99%

See 1 more Smart Citation

An Unusual Case of Cholestatic Hepatitis

Al-Taee

Gremida

Cheung

et al. 2017

Journal of Gastroenterology and Hepatology Research

View full text Add to dashboard Cite

resection of the primary tumor. Here we present an unusual case of non-metastatic hepatic dysfunction secondary to renal cell carcinoma, also known as Stauffer's syndrome, in a 55-year old patient who presented with liver synthetic dysfunction and notable hyperbilirubinemia. Unlike earlier reports, the icteric variant of Staffer's syndrome has been emerging as the predominantly reported variant in the recent literature. Moreover, poor correlation between the severity of hepatic dysfunction and the liver biopsy findings was noted. The variable and non-specific presenting symptoms and signs as well as the need for extensive evaluation for abnormal liver chemistry usually results in a delay in the diagnosis of the primary tumor. Therefore, physicians need to be familiar with this clinical entity as a possible reversible etiology of liver chemistry abnormalities in patients with renal and other solid tumors as this may guide further investigations, lead to earlier diagnosis and treatment of the primary tumor, and ultimately improve outcomes. INTRODUCTIONNon-metastatic hepatic dysfunction secondary to renal cell carcinoma, also known as Stauffer's syndrome, was first described by Stauffer in 1961 [1] . The pathophysiology has not been completely elucidated so far. Surgical resection of the primary tumor is characteristically associated with reversal of liver chemistry abnormalities [2] . CASE PRESENTATIONA 55-year-old Caucasian male with a past medical history of type 2 diabetes mellitus and benign prostatic hyperplasia presented to the emergency room with the chief complaint of worsening abdominal ABSTRACTRenal cell carcinoma can present with a variety of paraneoplastic syndromes. Reversible hepatic dysfunction in the setting of nonmetastatic renal cell carcinoma is a rare paraneoplastic phenomenon that was first described by Stauffer in 1961. This clinical entity is characterized by reversal of liver chemistry abnormalities after CASE REPORT

show abstract

Section: Al-taee Am Et Al Non-metastatic Hepatic Dysfunctionmentioning

confidence: 99%

“…The pathophysiology has not been completely elucidated so far. Surgical resection of the primary tumor is characteristically associated with reversal of liver chemistry abnormalities [2] . …”

mentioning

confidence: 99%

An Unusual Case of Cholestatic Hepatitis

Al-Taee

Gremida

Cheung

et al. 2017

Journal of Gastroenterology and Hepatology Research

View full text Add to dashboard Cite

show abstract

“…Paraneoplastic endocri nopathies [3,4] associated with renal cell carcinoma have also been described previously, which include inap propriate or ectopic secretion of parathormone [ Comparing groups of stages 1,2,3 and 4 with each other by one-way Anova (p < 0.005), the higher the stage, the larger the decrease in serum iron, hemoglobin, hematocrit and MCV. Comparing the groups of different stages of renal cell carcinoma with the control group by Student's t test (p < 0.05), a significant decrease in serum iron, hemoglobin, hematocrit and MCV in patients with renal cell carcinoma was found.…”

Section: Introductionmentioning

confidence: 99%

Serum Iron as a Tumor Marker in Renal Cell Carcinoma

Chen²,

Chen³

et al. 1991

Eur Urol

View full text Add to dashboard Cite

Serum acute phase reactants and prognosis in renal cell carcinoma

Ljungberg

Grankvist

Rasmuson

1995

Cancer

View full text Add to dashboard Cite

Background. Inflammatory parameters as acute phase proteins commonly are elevated in patients with renal cell carcinoma. Some of these acute phase reactants have been proposed to influence survival. Methods. In 170 patients with renal cell carcinoma, the authors studied six acute phase reactant parameters (erythrocyte sedimentation rate [ESR], C‐reactive protein, haptoglobin, ferritin, orosomucoid, and alphal‐antitrypsin) that were compared with stage and grade. Results. The acute phase reactants correlated well with each other and with stage and grade. All acute phase reactants separately were found to be significant prognostic factors of survival using the log rank test. However, when a multivariate Cox analysis was performed, only stage, grade, and ESR were identified as independent prognostic factors, whereas the other factors were not. Conclusions. The study suggests that all acute phase reactants separately were found to be significant univariate prognostic factors, but in a multivariate analysis, ESR was the only independent prognostic parameter for survival.

show abstract

Hepatic Dysfunction in Renal Carcinoma

Cited by 11 publications

References 19 publications

An Unusual Case of Cholestatic Hepatitis

An Unusual Case of Cholestatic Hepatitis

Serum Iron as a Tumor Marker in Renal Cell Carcinoma

Serum acute phase reactants and prognosis in renal cell carcinoma

Contact Info

Product

Resources

About